Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy.
Hester J Scheffer, Karin Nielsen, Marcus C de Jong...
https://pubmed.ncbi.nlm.nih.gov/24656178/Actively Recruiting
Led by Amsterdam UMC, location VUmc · Updated on 2026-08-28
27
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are evaluating the short- and long-term effects of irreversible electroporation IRE in adults over 18 years old who have recurrent pelvic tumors that cannot be treated with surgery, thermal ablation, or radiotherapy. This observational cohort study uses a registry combining past and new patient data to understand if IRE is safe and effective for controlling tumor recurrence in this population. The study includes retrospective data collected from December 2012 through April 2025 and will continue prospectively with new cases thereafter. Participants undergo the IRE procedure, which involves applying electrical pulses to destroy tumor cells without using heat. The treatment duration ranges from 30 minutes to 2 hours during the actual procedure. Participants provide data through routine clinical care, including imaging scans and follow-up assessments. Researchers monitor adverse events and nerve injuries for up to 5 years after treatment. They also track survival outcomes and tumor progression over a period of up to 10 years, aiming to understand safety and long-term effects of IRE for recurrent pelvic tumors.
CONDITIONS
Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
S
Sonia Triggiani, Radiologist
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Amsterdam UMC, location VUmc
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - 30 minutes to 2 hours
Participants undergo the irreversible electroporation procedure to treat recurrent pelvic tumors.
1 procedure visit
Duration - Up to 10 years
Participants are monitored for safety, nerve injury, survival, and tumor progression through regular clinical assessments and imaging for up to 10 years.
Visits and assessments at regular intervals over 10 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Hester J Scheffer, Karin Nielsen, Marcus C de Jong...
https://pubmed.ncbi.nlm.nih.gov/24656178/L G P H Vroomen, H J Scheffer, M C A M Melenhorst...
https://pubmed.ncbi.nlm.nih.gov/28470395/Christoph Niessen, Ernst-Michael Jung, Andreas G Schreyer...
https://pubmed.ncbi.nlm.nih.gov/23668891/Govindarajan Narayanan, Ashwin M Mahendra, Nicole T Gentile...
https://pubmed.ncbi.nlm.nih.gov/38943032/Xiaomei Luo, Zilin Qin, Huimin Tao...
https://pubmed.ncbi.nlm.nih.gov/28927918/Helmut Schoellnast, Sebastien Monette, Paula C Ezell...
https://pubmed.ncbi.nlm.nih.gov/23011210/Willemien van den Bos, Hester J Scheffer, Jantien A Vogel...
https://pubmed.ncbi.nlm.nih.gov/26703782/H J Seddon
https://pubmed.ncbi.nlm.nih.gov/20784403/Amsterdam UMC, location VUmc
Lead Sponsor